498 related articles for article (PubMed ID: 25271622)
21. Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease.
Paz K; Flynn R; Du J; Qi J; Luznik L; Maillard I; MacDonald KP; Hill GR; Serody JS; Murphy WJ; Sage PT; Sharpe AH; Miklos D; Cutler CS; Koreth J; Antin JH; Soiffer RJ; Ritz J; Bradner JE; Melnick AM; Blazar BR
Blood; 2019 Jan; 133(1):94-99. PubMed ID: 30279226
[TBL] [Abstract][Full Text] [Related]
22. Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease.
Flynn R; Allen JL; Luznik L; MacDonald KP; Paz K; Alexander KA; Vulic A; Du J; Panoskaltsis-Mortari A; Taylor PA; Poe JC; Serody JS; Murphy WJ; Hill GR; Maillard I; Koreth J; Cutler CS; Soiffer RJ; Antin JH; Ritz J; Chao NJ; Clynes RA; Sarantopoulos S; Blazar BR
Blood; 2015 Jun; 125(26):4085-94. PubMed ID: 25852057
[TBL] [Abstract][Full Text] [Related]
23. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans.
Srinivasan M; Flynn R; Price A; Ranger A; Browning JL; Taylor PA; Ritz J; Antin JH; Murphy WJ; Luznik L; Shlomchik MJ; Panoskaltsis-Mortari A; Blazar BR
Blood; 2012 Feb; 119(6):1570-80. PubMed ID: 22072556
[TBL] [Abstract][Full Text] [Related]
24. New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions.
Saidu NEB; Bonini C; Dickinson A; Grce M; Inngjerdingen M; Koehl U; Toubert A; Zeiser R; Galimberti S
Front Immunol; 2020; 11():578314. PubMed ID: 33162993
[TBL] [Abstract][Full Text] [Related]
25. Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease.
Le Huu D; Kimura H; Date M; Hamaguchi Y; Hasegawa M; Hau KT; Fujimoto M; Takehara K; Matsushita T
J Dermatol Sci; 2014 Jun; 74(3):214-21. PubMed ID: 24679982
[TBL] [Abstract][Full Text] [Related]
26. Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host disease.
Paz K; Flynn R; Du J; Tannheimer S; Johnson AJ; Dong S; Stark AK; Okkenhaug K; Panoskaltsis-Mortari A; Sage PT; Sharpe AH; Luznik L; Ritz J; Soiffer RJ; Cutler CS; Koreth J; Antin JH; Miklos DB; MacDonald KP; Hill GR; Maillard I; Serody JS; Murphy WJ; Munn DH; Feser C; Zaiken M; Vanhaesebroeck B; Turka LA; Byrd JC; Blazar BR
Am J Transplant; 2019 Jun; 19(6):1820-1830. PubMed ID: 30748099
[TBL] [Abstract][Full Text] [Related]
27. Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans.
Flynn R; Du J; Veenstra RG; Reichenbach DK; Panoskaltsis-Mortari A; Taylor PA; Freeman GJ; Serody JS; Murphy WJ; Munn DH; Sarantopoulos S; Luznik L; Maillard I; Koreth J; Cutler C; Soiffer RJ; Antin JH; Ritz J; Dubovsky JA; Byrd JC; MacDonald KP; Hill GR; Blazar BR
Blood; 2014 Jun; 123(25):3988-98. PubMed ID: 24820310
[TBL] [Abstract][Full Text] [Related]
28. B lymphocytes inactivation by Ibrutinib limits endometriosis progression in mice.
Riccio LGC; Jeljeli M; Santulli P; Chouzenoux S; Doridot L; Nicco C; Reis FM; Abrão MS; Chapron C; Batteux F
Hum Reprod; 2019 Jul; 34(7):1225-1234. PubMed ID: 31247078
[TBL] [Abstract][Full Text] [Related]
29. Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.
Stiff A; Trikha P; Wesolowski R; Kendra K; Hsu V; Uppati S; McMichael E; Duggan M; Campbell A; Keller K; Landi I; Zhong Y; Dubovsky J; Howard JH; Yu L; Harrington B; Old M; Reiff S; Mace T; Tridandapani S; Muthusamy N; Caligiuri MA; Byrd JC; Carson WE
Cancer Res; 2016 Apr; 76(8):2125-36. PubMed ID: 26880800
[TBL] [Abstract][Full Text] [Related]
30. Successful management of acute graft-versus-host disease with ibrutinib during cord blood transplantation for germline
Uchimura A; Yasuda H; Onagi H; Inano T; Shirane S; Ishii M; Azusawa Y; Hamano Y; Eguchi H; Arai M; Ando J; Ando M
Heliyon; 2024 Jan; 10(2):e24801. PubMed ID: 38312561
[TBL] [Abstract][Full Text] [Related]
31. Ibrutinib suppresses alloantibody responses in a mouse model of allosensitization.
Kim I; Wu G; Chai NN; Klein AS; Jordan S
Transpl Immunol; 2017 Dec; 45():59-64. PubMed ID: 28951258
[TBL] [Abstract][Full Text] [Related]
32. Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production.
Du J; Paz K; Flynn R; Vulic A; Robinson TM; Lineburg KE; Alexander KA; Meng J; Roy S; Panoskaltsis-Mortari A; Loschi M; Hill GR; Serody JS; Maillard I; Miklos D; Koreth J; Cutler CS; Antin JH; Ritz J; MacDonald KP; Schacker TW; Luznik L; Blazar BR
Blood; 2017 May; 129(18):2570-2580. PubMed ID: 28254742
[TBL] [Abstract][Full Text] [Related]
33. Drug repurposing: Ibrutinib exhibits immunosuppressive potential in organ transplantation.
Zhang Q; Chen J; Gao H; Zhang S; Zhao C; Zhou C; Wang C; Li Y; Cai Z; Mou L
Int J Med Sci; 2018; 15(11):1118-1128. PubMed ID: 30123049
[TBL] [Abstract][Full Text] [Related]
34. Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase.
Davids MS; Brown JR
Future Oncol; 2014 May; 10(6):957-67. PubMed ID: 24941982
[TBL] [Abstract][Full Text] [Related]
35. Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.
Gayko U; Fung M; Clow F; Sun S; Faust E; Price S; James D; Doyle M; Bari S; Zhuang SH
Ann N Y Acad Sci; 2015 Nov; 1358():82-94. PubMed ID: 26348626
[TBL] [Abstract][Full Text] [Related]
36. Ibrutinib for the treatment of chronic graft-vs-host disease in pediatric hematopoietic stem cell transplant patients: A single-center experience.
Teusink-Cross A; Davies SM; Grimley MS; Chandra S; Flannery A; Dandoy CE; Nelson AS; Marsh RA; Jacoby B; Lane A; Khandelwal P
Pediatr Transplant; 2020 May; 24(3):e13692. PubMed ID: 32202691
[TBL] [Abstract][Full Text] [Related]
37. Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes.
Wei L; Su YK; Lin CM; Chao TY; Huang SP; Huynh TT; Jan HJ; Whang-Peng J; Chiou JF; Wu AT; Hsiao M
Oncotarget; 2016 Oct; 7(43):69961-69975. PubMed ID: 27564106
[TBL] [Abstract][Full Text] [Related]
38. The promising impact of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the management of lymphoid malignancies.
Bhatt V; Alejandro L; Michael A; Ganetsky A
Pharmacotherapy; 2014 Mar; 34(3):303-14. PubMed ID: 24338680
[TBL] [Abstract][Full Text] [Related]
39. B cells in chronic graft-versus-host disease.
McManigle W; Youssef A; Sarantopoulos S
Hum Immunol; 2019 Jun; 80(6):393-399. PubMed ID: 30849450
[TBL] [Abstract][Full Text] [Related]
40. Novel Approaches to the Treatment of Chronic Graft-Versus-Host Disease.
Zeiser R
J Clin Oncol; 2023 Apr; 41(10):1820-1824. PubMed ID: 36800551
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
